Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Former CMS Chief Scully’s Perspective On The Changes In Washington

Executive Summary

In a speech before the Food and Drug Law Institute's conference on collaboration between CMS and FDA, Tom Scully, with his usual candor and humor, gave his views on what the outcome of the national elections could mean to the health care industry and on some of the proposals being floated in Washington. Below are some excerpts from his presentation on Nov. 18 in Washington, D.C. Scully served as CMS administrator from 2001 to 2003. He currently divides his time between the law firm Alston & Bird, where he is senior counsel, and the private equity firm Welsh, Carson, Anderson & Stowe, where he is a general partner.

You may also be interested in...



Medicaid Rebates For Part D Duals Would Jeopardize Program, Experts Say

Some Medicare Part D experts are warning of the unintended consequences that could result from applying Medicaid drug pricing policy to low-income seniors enrolled in Medicare Part D drug plans

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Deal Watch: Sanofi, Boehringer Swap Side Businesses

Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.

UsernamePublicRestriction

Register

PS050389

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel